EN.10

QCGC Research is proud to partner with the Canadian Cancer Trials Group and ANZGOG, on the EN.10/TAPER Study.

EN.10/TAPER is a Phase II trial led by Professor Alison Brand AM (ANZGOG), and Kathy Han and Jessica McAlpine (CCTG) that focuses on finding the best follow-up treatment after surgery for early-stage endometrial cancer. Specifically, the trial looks at cancers with certain genetic traits (Pole-mutated and p53-wildtype/NSMP). The main goal is to see how often cancer returns in the pelvic area over a three-year period when a reduced or customised post-surgery treatment is used.

After surgery to remove early-stage endometrial cancer, doctors often recommend additional treatments like radiotherapy or chemotherapy to lower the risk of the cancer coming back.

Some cancers have a very low chance of returning.

This study aims to find out if reducing or skipping these additional treatments is safe and can improve the patient’s quality of life. In this trial, researchers will examine a sample of each participant’s cancer taken during surgery. Based on certain characteristics of the cancer, participants will be placed in one of three groups (sub-studies) to receive tailored treatment.

Trial Sites

Internationally, there are 32 sites (Canada, The Netherlands, USA, Italy and New Zealand). Nationally, there are 10 sites.

Recruitment

The EN.10 Study opened for recruitment in December 2022.

The study aims to recruit 325 participants from national and international sites. 107 participants have been enrolled to date.